Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577797 | 0.87 | GAA (0.49) | GAAALDH1A1MCHR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5577938 | 0.87 | CXCR3 (0.44) | CXCR3L3MBTL1SMN1; SMN2 | |
| SCHEMBL5577758 | 0.86 | LMNA (0.41) | ALDH1A1 | |
| SCHEMBL5577416 | 0.85 | ALDH1A1 (0.46) | GAAALDH1A1CXCR3MCHR1L3MBTL1 | |
| SCHEMBL5577473 | 0.84 | ALDH1A1 (0.51) | GAAALDH1A1MCHR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5577709 | 0.84 | GAA (0.51) | GAAALDH1A1MCHR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5577800 | 0.83 | GAA (0.45) | GAAALDH1A1CXCR3MCHR1L3MBTL1 | |
| SCHEMBL5577798 | 0.83 | GAA (0.46) | GAAALDH1A1CXCR3L3MBTL1SMN1; SMN2 | |
| SCHEMBL5577557 | 0.81 | SCN2A (0.46) | GAAALDH1A1CXCR3MCHR1L3MBTL1 | |
| SCHEMBL5577871 | 0.81 | DRD2 (0.48) | GAAMCHR1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | GAA 3806/4885ALDH1A1 1147/4885CXCR3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.